scholarly journals Medical Treatment for Endometriosis: Tolerability, Quality of Life and Adherence

2021 ◽  
Vol 2 ◽  
Author(s):  
Giussy Barbara ◽  
Laura Buggio ◽  
Federica Facchin ◽  
Paolo Vercellini

Endometriosis is associated with painful symptoms, infertility, sexological difficulties, and psychological suffering. All these symptoms have a negative impact on the overall quality of life of women with the disease, with significant personal, social and economic costs. Several medical options are available to manage symptomatic endometriosis. The pharmacological treatment for endometriosis-related pain may be necessary for decades, or at least until there is a desire for pregnancy or physiologic menopause occurs. In this perspective, clinicians should consider not only the efficacy, but also side effects, tolerability, and costs, along with women's preferences toward different treatments. In this mini-review, we analyzed the pros and cons of the available drugs for the medical therapy of endometriosis, such as estrogen-progestins, progestins, GnRH agonist and GnRH antagonists.

2019 ◽  
Vol 7 (2) ◽  
pp. 46-48
Author(s):  
Maria Perfecta Fernandez Gonzalez ◽  
Aurea Maria Gomez Marquez ◽  
Maria Pereiro Sanchez ◽  
Raquel Iglesias Varela ◽  
Jose Luis Sastre Moral  ◽  
...  

Few side effects of cancer treatment are more fearsome for patients than nausea and vomiting. Although both can result from surgery or radiation therapy, chemotherapy-induced nausea and vomiting (CINV) are potentially the most severe and the most distressing ones. Despite recent advances in the prevention of emesis induced by chemotherapy, its control remains to be insufficient in 20-25%.1s of patients, with the ensuing negative impact on their quality of life. In this small review, we intend to analyze some critical aspects related to the approach of antiemetic therapy in the clinical practice in haematological patients.


1970 ◽  
Vol 4 (1) ◽  
Author(s):  
Ikeu Nurhidayah ◽  
Sri Hendrawati ◽  
Henny S. Mediani ◽  
Fanny Adistie

Kanker anak merupakan penyakit yang memerlukan pengobatan dan perawatan berkelanjutan. Pengobatan kemoterapi yang berkelanjutan pada anak dengan kanker, selain memiliki efek terapeutik juga menyebabkan berbagai efek samping. Hal ini dapat berdampak terhadap kualitas hidup anak, meliputi fungsi fisik, emosi, sosial, psikologis, sekolah, dan kognitif. Tujuan penelitian ini untuk mengidentifikasi kualitas hidup pada anak dengan kanker. Penelitian ini menggunakan mixed method dengan strategi eksplanatoris sekuensial. Sampel penelitian kuantitatif dengan 60 responden. Kualitas hidup pada anak diukur dengan menggunakan instrumen PedsQoL Generic 4.0 dan PedsQoL Cancer Module 3.0. Analisis data dilakukan menggunakan nilai mean. Penelitian kualitatif menggunakan 10 partisipan dan pengumpulan data dengan pedoman wawancara. Analisis data menerapkan teknik analysis interactive model dengan tahapan pengumpulan data, reduksi data, penyajian data, dan penarikan kesimpulan. Penelitian ini dilaksanakan di RSUP Dr. Hasan Sadikin Bandung. Hasil penelitian menunjukkan 32 orang (53,3%) anak kanker memiliki kualitas hidup buruk, dengan nilai terendah pada fungsi sekolah dan kekhawatiran anak dalam menghadapi pengobatan dan penyakit.Kualitas hidup yang buruk ini berpengaruh terhadap fungsi fisik, emosi, sosial, psikologis, sekolah, dan kognitif sehingga tumbuh kembang anakpun terganggu. Salah satu upaya untuk meningkatkan kualitas hidup pada anak dengan menyediakan kesempatan bagi anak untuk tetap belajar dan saling berinteraksi dan dukungan dari perawat.Kata kunci: Anak, kanker, kualitas hidup. Quality of Life of Children Living with CancerAbstractCancer in children is an illness that needs continuous medication and treatment so that it has to be managed with high quality care. Continuous chemotherapy treatment in children with cancer, besides giving therapeutic effect, it also causes various side effects. These side effects could have negative effect for quality of life of the children, including physical, emotional, social, psychological, school, and cognitive functions. The aim of this study was to identify quality of life of children living with cancer. This study used mixed method design with sequential explanatory strategy. The quantitative study recruited 60 samples of children living with cancer. The quality of life of the children was measured using PedsQol Generic 4.0 and PedsQoL Cancer Module 3.0. Data were analyzed using mean score. The qualitative study recruited 10 participants and the data were collected using semi-structured interview. Qualitative data analysis used interactive analysis model which consisted data collection, data reduction, data presentation, and conclusion phases. Both of the studies were conducted at Dr. Hasan Sadikin Hospital Bandung. The results showed that based on PedsQol Generic 4.0, most of the children (53.3%) has low quality of life, with the school function as the lowest score. Based on PedQoL Cancer Module 3.0, most of children (61.7%) also has low quality of life, particularly in children’s worriedness aspect when dealing with treatment and their illness which has lowest score. This low quality of life would have negative impact towards children’s physical, emotional, social, psychological, school and cognitive function, so that it disturbed the children’s growth and development. One of efforts that can be done is to provide opportunities for children to continue studying and interaction in hospital, as well as an additional schedule for psychology therapies to help children overcome the negative emotion during their treatment.Keywords: Cancer, children, quality of life.


2018 ◽  
Vol 12 ◽  
pp. 117822341875803 ◽  
Author(s):  
John Syrios ◽  
Evelina Pappa ◽  
Nikolaos Volakakis ◽  
Anastasios Grivas ◽  
John Alafis ◽  
...  

Purpose: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (anti-HER2) antibody delivered intravenously, has revolutionized the treatment of patients with breast cancer overexpressing HER2 protein. Recently, a newer subcutaneous formulation was shown to have comparable efficacy to the initial intravenous trastuzumab. In this study, we aimed to evaluate the impact of subcutaneous trastuzumab on the health-related quality of life (HRQoL) of patients diagnosed with early or metastatic HER2-overexpressing breast cancer. Methods: Patients were provided with the EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) and the BR-23 questionnaires. The scoring of questionnaires and patient’s sociodemographic and clinicopathologic characteristics were recorded and analyzed by descriptive and correlation statistics employing t test and 2-way analysis of variance. Results: A total of 163 patients agreed to participate in the study. About 90 of 163 patients (55.21%) received subcutaneous trastuzumab and 21 patients intravenous trastuzumab (12.88%). A control group of 52 HER2+ patients received chemotherapy without trastuzumab (31.90%). Patients receiving subcutaneous trastuzumab were older and of more advanced disease stage compared with those receiving chemotherapy (58.5 vs 51 years, 39.8% vs 28.8% advanced disease). In univariate analysis, subcutaneous trastuzumab was associated with less nausea and vomiting ( P = .002) but worse cognitive function ( P = .013) and dyspnea ( P = .042). Patients who have received >8 cycles of subcutaneous trastuzumab reported less diarrhea ( P = .049) and systemic therapy side effects ( P = .015). Multivariate analysis showed that patients without comorbidity receiving subcutaneous trastuzumab had less treatment side effects, less upset by hair loss, and higher emotional functioning. Of note, mastectomy and subcutaneous trastuzumab were associated with improved role functioning ( P = .021). In metastatic disease, no negative impact of subcutaneous trastuzumab on HRQoL was found. Conclusions: The administration of subcutaneous trastuzumab improved certain symptoms and did not adversely affect most of the assessed functional scales. Particularly, in the metastatic setting, subcutaneous trastuzumab had no negative impact on HRQoL.


Author(s):  
Joshua A. Sloan ◽  
Philip O. Katz

The medical and lay literature has exploded with reports of adverse events associated with proton pump inhibitors over the last 10 to 15 years. The dissemination of these reports to patients and clinicians have created substantial concerns regarding what has been an exceptionally valuable drug class, dramatically improving patient quality of life, and in many cases preventing life threatening side effects of other medication. Patients are more frequently seeking to avoid these medications, and practitioners are reducing or discontinuing them to the patient’s detriment due to a misunderstanding of the data. This review will discuss the data regarding the most commonly publicized adverse events and attempt to put them in perspective.


2021 ◽  
Vol 38 (2) ◽  
Author(s):  
Mira Sonneborn-Papakostopoulos ◽  
Clara Dubois ◽  
Viktoria Mathies ◽  
Mara Heß ◽  
Nicole Erickson ◽  
...  

AbstractCancer-related malnutrition has a high prevalence, reduces survival and increases side effects. The aim of this study was to assess oncology outpatients and risk of malnutrition. Reported symptoms and quality of life (QoL) in patients found to be at risk of malnutrition or malnourished were compared to patients without malnutrition. Using a standardized questionnaire, the European Organization for Research and Treatment of Cancer Questionnaire for Quality of Life and the Mini Nutritional Assessment (MNA), patients in an outpatient cancer clinic undergoing chemotherapy treatment at a German University Hospital were assessed for nutrition, risk of malnutrition and quality of life. Based on the MNA, 39 (45.9%) patients were categorized as malnourished or at risk for malnutrition. Loss of appetite (n = 37.6%, p < 0.001) and altered taste sensation (n = 30,3%, p < 0.001) were the symptoms most frequently associated with reduced food intake. Patients with risk of malnutrition scored lower on the global health status (n = 48.15%, p = 0.001). Side effects of cancer treatments lead to a higher risk of malnutrition and as a consequence lower QoL. These side effects should be addressed more efficiently in cancer care.


Author(s):  
Germina-Alina Cosma ◽  
Alina Chiracu ◽  
Amalia Raluca Stepan ◽  
Marian Alexandru Cosma ◽  
Marian Costin Nanu ◽  
...  

The aim of this study was to analyze athletes’ quality of life during the COVID-19 pandemic. The study involved 249 athletes between 15 and 35 of age, M = 21.22, SD = 5.12. The sample was composed of eight Olympic Games medalists, three European medalists, 67 international medalists, and 63 national medalists. The instruments used were: (1) COVID-19 Anxiety Scale, (2) Athlete Quality of Life Scale, (3) Impact of Pandemic on Athletes Questionnaire, and (4) International Personality Item Pool (IPIP Anxiety, Depression, and Vulnerability Scales). The results indicate significant differences in COVID-19 anxiety depending on the sport practiced, F (9239) = 3.81, p < 0.01, showing that there were significant differences between sports. The negative impact of the COVID-19 pandemic mediates the relationship between trait anxiety and the athletes’ quality of life. The percentage of mediation was 33.9%, and the indirect effect was −0.11, CI 95% (−0.18, −0.03), Z = −2.82, p < 0.01. Trait anxiety has an increasing effect on the intensity of the negative impact of the COVID-19 pandemic, 0.23, CI 95% (.10, 0.35), Z = 3.56, p < 0.01, and the negative impact of the COVID-19 pandemic has a decreasing effect on quality of life, −0.47, CI 95% (−0.67, −0.27), Z = −4.62, p < 0.01. Gender and age did not moderate the relationship between the negative impact of COVID-19 and athletes’ quality of life. The results of the study highlighted the impact that social isolation and quarantine have on athletes’ affective well-being.


2021 ◽  
pp. 136749352110129
Author(s):  
Alice S Schamong ◽  
Hannah Liebermann-Jordanidis ◽  
Konrad Brockmeier ◽  
Elisabeth Sticker ◽  
Elke Kalbe

Congenital heart disease (CHD) is a major global health problem. Until recently, the siblings of this group did not receive much attention. This review, conducted from November 2019 to October 2020, aims to summarize knowledge about psychosocial well-being and quality of life (QoL), associated factors, and interventions for siblings of children with CHD. Systematic searches were conducted in PubMed, PsycINFO, PsycARTICLES, Web of Science via EBSCOhost, and CENTRAL. Twelve articles were included. Results showed that psychosocial well-being was impaired in 14% to 40% of siblings. Negative impact of illness was highest for CHD siblings compared to siblings of children with cancer, cystic fibrosis, or diabetes. QoL was impaired in up to one-third. Siblings of children with CHD and cancer rated their QoL lower than those of siblings of children with cystic fibrosis or type-1 diabetes. Associated factors were sibling age, gender, socioeconomic status, miscarriage, previous sibling death, visibility of illness, and severity of condition. Only one of two interventions focused on siblings of CHD children. Although data are scarce and inhomogeneous, it indicates that siblings of CHD children suffer from lower psychosocial well-being and QoL than siblings of children with other chronic conditions. Interventions to improve their situation should be developed.


Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Leonessa Boing ◽  
Tatiana do Bem Fretta ◽  
Melissa de Carvalho Souza Vieira ◽  
Gustavo Soares Pereira ◽  
Jéssica Moratelli ◽  
...  

Abstract Background Breast cancer is a global public health issue. The side effects of the clinical treatment can decrease the quality of life of these women. Therefore, a healthy lifestyle is essential to minimize the physical and psychological side effects of treatment. Physical activity has several benefits for women with breast cancer, and Pilates solo and belly dancing can be an enjoyable type of physical activity for women with breast cancer undergoing clinical treatment. The purpose of this study is to provide a Pilates solo and a belly dance protocol (three times per week/16 weeks) for women undergoing breast cancer treatment and compare its effectiveness with that in the control group. Methods The participants will be allocated to either the intervention arm (Pilates solo or belly dance classes three times per week for 16 weeks) or a control group (receipt of a booklet on physical activity for patients with breast cancer and maintenance of habitual physical activity routine). The Pilates solo and belly dance classes will be divided into three stages: warmup and stretching, the main stage, and relaxation. Measurements of the study outcomes will take place at baseline; postintervention; and 6, 12, and 24 months after the end of the intervention (maintenance period). The data collection for both groups will occur with a paper questionnaire and tests covering general and clinical information. The primary outcome will be quality of life (EORT QLQ-C30 and EORT QLQ-BR23), and secondary outcomes will be physical aspects such as cardiorespiratory fitness (6-min walk test and cycle ergometer), lymphedema (sum of arm circumference), physical activity (IPAQ short version), disabilities of the arm (DASH), range of motion (goniometer test), muscular strength (dynamometer test) and flexibility (sit and reach test), and psychological aspects such as depressive symptoms (Beck Depression Inventory), body image (Body Image After Breast Cancer Questionnaire), self-esteem (Rosenberg), fatigue (FACT-F), pain (VAS), sexual function (FSFI), and sleep quality (Pittsburgh Sleep Quality Index). Discussion In view of the high prevalence of breast cancer among women, the implementation of a specific protocol of Pilates solo and belly dancing for patients with breast cancer is important, considering the necessity to improve their physical and psychological quality of life. Pilates solo and belly dancing are two types of physical activity that involve mental and physical concentration, music, upper limb movements, femininity, and social involvement. An intervention with these two physical activities could offer options of supportive care to women with breast cancer undergoing treatment, with the aim being to improve physical and psychological quality of life. Trial registration ClinicalTrials.gov, NCT03194997. Registration date 12 August 2017. Universal Trial Number (World Health Organization), U1111-1195-1623.


Sign in / Sign up

Export Citation Format

Share Document